San Antonio, Texas — February 9, 2026 — Leads & Copy — bioAffinity Technologies Inc. (Nasdaq: BIAF; BIAFW) has appointed David Ost, MD, MPH, Daniel Sterman, MD, and J. Scott Ferguson, MD, to its Medical and Scientific Advisory Board.
The appointments align with bioAffinity’s clinical, scientific, and commercial goals, including integrating CyPath® Lung into the standard of care for indeterminate pulmonary nodules. CyPath® Lung is a noninvasive diagnostic test for lung cancer.
Dr. Ost is a professor of medicine and chief of Pulmonary, Critical Care, and Sleep Medicine at MD Anderson Cancer Center. Dr. Sterman is a professor of medicine and chief of the Division of Pulmonary, Critical Care, and Sleep Medicine at NYU Langone Health. Dr. Ferguson is a professor of medicine and director of Interventional Pulmonology at the University of Wisconsin School of Medicine and Public Health.
The new members join current board members David Hill, MD, Neil Alexis, PhD, Sheila Habib, MD, and Sandeep Bansal, MD.
According to bioAffinity Technologies Chief Medical Officer Gordon Downie, MD, PhD, the Medical and Scientific Advisory Board’s experience will help improve outcomes for patients by detecting lung cancer early.
Dr. Ost focuses on improving lung cancer diagnosis, staging, and treatment. Dr. Sterman researches gene therapy and immunotherapy to treat lung cancer and mesothelioma. Dr. Ferguson specializes in treating complex lung conditions and is known for his advanced diagnostic techniques for lung cancer, thoracic oncology, and therapeutic bronchoscopy.
bioAffinity Technologies President and CEO Maria Zannes said the appointments will strengthen the panel of clinical and scientific leaders guiding the company’s work to advance CyPath® Lung.
CyPath® Lung uses flow cytometry and artificial intelligence to identify cell populations in patient sputum that indicate malignancy. It incorporates a fluorescent porphyrin taken up by cancer cells. Clinical study results showed 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in high-risk patients with small indeterminate lung nodules less than 20 millimeters.
bioAffinity Technologies, Inc. focuses on noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. Its first product, CyPath® Lung, is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies.
Source: bioAffinity Technologies, Inc.
